Editorial
 THE ANDA GALLOP   
 Wednesday, January 16, 2019 
 In spite of several headwinds including intermittent warning letters by the US FDA even to major Indian companies, the Indian pharmaceutical companies and their subsidiaries have shown an impressive performance 
  Past Editorial...  
TODAY'S NEWS
18:00  [IST]Therachon gets US FDA orphan drug status for apraglutide for short bowel syndrome treatment
17:00  [IST]Pacira Pharma phase 4 study of Exparel in patients undergoing C-section achieves primary endpoint with significant reductions in opioid consumption
16:00  [IST]Targovax gets European patent for mutant-RAS neoantigen & mutant-RAS specific T cells
15:00  [IST]OKI, ARC Innovation Center at Sheba join forces to prevent dementia
14:30  [IST]US FDA grants orphan drug designation to Bridge Biotherapeutics' BBT-877 in IPF
14:00  [IST]Centinel Spine completes initial cases with FLX Platform of 3D-Printed All-Titanium Interbody devices
more news >>
TOP NEWS
08:00  [IST]Gujarat based companies propose big ticket investments worth Rs.8,223 crore through 273 MoUs
08:00  [IST]Online pharmacies wait for final order on e-pharmacy regulations: Dr Jagashetty
08:00  [IST]Sub-committee on compensation related to medical devices to meet industry associations next week
08:00  [IST]Every country has its own challenges to address issue of rare disease policy: Prasanna Shirol
08:00  [IST]IPA-Karnataka to organise seminar on 'Recent developments in product development & tech transfer' on Feb 2
08:00  [IST]Health ministry to roll out new e-pharmacy regulations soon as draft rules being reviewed by PMO
more news >>
YESTERDAY'S NEWS
18:00  [IST]US FDA seeks additional data from Actelion's sNDA for Opsumit to treat CTEPH
17:10  [IST]ICMRs report on pollution put on debate to consider pollution a major factor leading to the cause of death
17:00  [IST]AIVITA Biomedical receives US FDA approval to initiate phase 1B melanoma trial
16:45  [IST]Governor asks IMA to work for standardisation of medical costs at VAICON-2019 in Hyderabad
16:00  [IST]Hondros College of Nursing introduces new Medical Laboratory Technology programme
15:30  [IST]Govt bans 80 more irrational FDCs; Delhi High Court rejects pharma firms’ plea to vacate ban on diabetes drugs
more news >>
INTERVIEW  
Rising burden of NCDs impacts Indian healthcare scene
Gagan Singh Bedi, managing director, AstraZeneca Pharma India Gagan-Singh-Bedi.jpg
Past Interviews...
 
  What's New?  
 
Opinion Poll
 
 
Will the central govt's decision to replace MCI with National Medical Commission boost the medical education scenario in the country?
 
 
 
   
 
  Corporate
Pharma Stocks
Executive Diary
Pharma People
Product Launches
  Special Features
Features
  Chronicle Pharmabiz Specials
Forthcoming
  Past
 
  Forthcoming Events
International
  Domestic
 
TENDERS & PROJECTS
Tenders & Enquiries
Pharma Projects
CORPORATE
Company Profile
Corporate Results
Corporate X-ray
Pharmabiz Studies of Top Companies
US FDA UPDATE
US FDA: ANDA
US FDA: Warnings
US FDA: Approved NMEs
US FDA: New Approvals
EXPORT & IMPORT
Drug Export Procedures
Drug Units With WHO GMP Certification
Pharma Export Data
Import Reg. Update
PHARMA LAWS & DOCUMENTS
Notifications
Pharma Regulations
Patent Laws and Amendments
Patent Scan
Documents
New Drug Approvals
Notified Prices
LIST OF LABS & GOVT. BODIES
Govt Recognised In-House R&D Units
AICTE Boards & Committees
List of Indian CROs
List of CROs (International)
Govt & approved labs of India
List of State Drugs Controllers
 
 
Chemspec_india_2019
anticounter_Panel_2019
Pharma_Proj
BioAsia
cphi-india_Banner-150x60
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |